

BRISTOL-MYERS SQUIBB, PHARMACEUTICAL GROUP
P.O. BOX 191, NEW BRUNSWICK, NJ 08903
EMERGENCY CONTACTS:

DATE: 3-4-93

DR. E. HAYES (TOXICOLOGY) (908) 519-2385 CHEMTREC (800) 424-9300

THE INFORMATION BELOW IS BELIEVED TO BE ACCURATE AND REPRESENTS THE BEST INFORMATION CURRENTLY AVAILABLE. HOWEVER, WE MAKE NO WARRANTY EXPRESS OR IMPLIED, WITH RESPECT TO SUCH INFORMATION, AND WE ASSUME NO LIABILITY RESULTING FROM ITS USE.

SUBSTANCE IDENTIFICATION

SUBSTANCE: KINEVAC (5 UG/VIAL)

CAS NUMBER NOT AVAILABLE RTECS NOT AVAILABLE

OTHER NAMES: SINCALIDE FOR INJECTION; OCTAPEPTIDE OF CHOLECYSTOKININ*

MOLECULAR FORMULA: NOT AVAILABLE MW: NOT AVAILABLE

* INFORMATION PERTAINS ONLY TO SINCALIDE

COMPONENTS

SUBSTANCE	WT%	HAZARD	EXPOSURE LIMIT
SINCALIDE SECTION	0.01	SEE "HEALTH EFFECTS"	NONE
SODIUM CHLORIDE	99.99	EYE IRRITANT	NONE

PRESENT AT < 1% OR USED FOR PH ADJUSTMENT:
NO OTHER CONSTITUENTS

PHYSICAL DATA

APPEARANCE: VIALS CONTAINING WHITE POWDER ODOR: NOT REMARKABLE
MELTING POINT: NOT AVAILABLE BOILING POINT: NOT APPLICABLE
VAPOR PRESSURE: NOT APPLICABLE
SOLUBILITY IN WATER: SOLUBLE

FIRE AND EXPLOSION DATA

FLASH POINT: NOT AVAILABLE FLAMMABILITY LIMITS: NOT AVAILABLE

EXTINGUISHING MEDIA: USE WATER.

AS WITH MOST ORGANIC SOLIDS, FIRE MAY BE POSSIBLE AT ELEVATED TEMPERATURES OR BY CONTACT WITH AN IGNITION SOURCE. ALTHOUGH MATERIAL HAS NOT BEEN SPECIFICALLY TESTED, FINE DUST SUSPENDED IN AIR IN SUFFICIENT CONCENTRATION AND IN THE PRESENCE OF AN IGNITION SOURCE MAY POSE A POTENTIAL EXPLOSION HAZARD. AS WITH ALL FIRES EVACUATE PERSONNEL TO SAFE AREA. WHEN THIS MATERIAL IS INVOLVED IN A FIRE A SELF-CONTAINED BREATHING APPARATUS AND FULL PROTECTIVE CLOTHING SHOULD BE WORN BY FIREFIGHTERS. USE WATER TO KEEP FIRE-EXPOSED CONTAINERS COOL. FIGHT FIRE FROM MAXIMUM SAFE DISTANCE OR USE AN UNMANNED MONITOR. MOVE CONTAINERS OF CHEMICALS FROM FIRE AREA IF THIS CAN BE DONE WITHOUT RISK. DIVERT RUNOFF TO A SAFE AREA. SEE REACTIVITY DATA.

\$PAGE

KINEVAC (5 UG/VIAL)

PAGE 2 OF 4

REACTIVITY DATA

STABILITY: STABLE UNDER NORMAL CONDITIONS
HAZARDOUS POLYMERIZATION: WILL NOT OCCUR
DECOMPOSITION: THERMAL DECOMPOSITION OR BURNING MAY PRODUCE NOXIOUS PRODUCTS INCLUDING: CO, CO₂, CL₂; HCL; NOX, SOX
INCOMPATIBILITY: NONE KNOWN

SPILL, LEAK & DISPOSAL PROCEDURES

SPILL: WEARING SUITABLE PROTECTIVE CLOTHING, SWEEP MATERIAL ONTO PAPER AND PLACE INTO AN APPROPRIATE FIBER DRUM FOR DISPOSAL. LATEX GLOVES, EYE PROTECTION AND A NIOSH-APPROVED DUST/MIST RESPIRATOR SHOULD BE WORN AS A MINIMUM PRECAUTION. ADDITIONAL PROTECTIVE CLOTHING/EQUIPMENT, MAY BE NEEDED DEPENDING ON THE EXTENT OF THE SPILL. THE SPILL AREA SHOULD BE VENTILATED AND DECONTAMINATED AFTER MATERIAL HAS BEEN PICKED UP.

DISPOSAL: DISPOSE OF IN ACCORDANCE WITH ALL LOCAL, STATE AND FEDERAL REGULATIONS OR WITH THE REGULATIONS OF THE COUNTRY IN WHICH THE MATERIAL IS USED.

HEALTH EFFECTS & FIRST AID

EXPOSURE LIMITS: NONE ESTABLISHED.

ROUTES OF ENTRY

KINEVAC CONTAINS SINCALIDE, A SYNTHETIC C-TERMINAL OCTAPEPTIDE OF THE HORMONE CHOLECYSTOKININ.

ORAL: NO SPECIFIC INFORMATION. MANY PEPTIDES ARE INACTIVATED IN THE GASTROINTESTINAL TRACT.

DERMAL: NO INFORMATION.

INHALATION: NO SPECIFIC INFORMATION. SOME PEPTIDES ARE ABSORBED AFTER INHALATION.

NOTE: THIS PRODUCT IS CONTAINED IN CLOSED OR SEALED VIALS. UNDER NORMAL CONDITIONS, PERSONS WOULD NOT BE EXPOSED TO POWDER. WHEN PREPARED, IN A CLINICAL SETTING, STERILE WATER FOR INJECTION IS ADDED TO THE VIAL CONTAINING SINCALIDE. THE RESULTING SOLUTION IS THEN INTENDED FOR INTRAVENOUS INJECTION, UNDER THE CARE OF A PHYSICIAN.

SYMPTOMS OF EXPOSURE

ORAL ROUTE: NO INFORMATION. DO NOT INGEST THIS SUBSTANCE.

INHALATION ROUTE: UNDER NORMAL CONDITIONS, THIS PRODUCT IS NOT AN INHALATION HAZARD, SINCE IT IS PROVIDED IN SEALED VIALS. IF MATERIAL BECOMES AEROSOLIZED AND IS INHALED, IT MAY HAVE POTENTIAL TO PRODUCE EFFECTS SEEN AFTER INJECTION.

DERMAL ROUTE: SODIUM CHLORIDE MAY CAUSE MILD SKIN IRRITATION. GLOVES AND PROTECTIVE CLOTHING SHOULD BE USED WHEN HANDLING LARGE QUANTITIES OF THIS PRODUCT.

EYE CONTACT: SODIUM CHLORIDE IS A MODERATE EYE IRRITANT. GOGGLES SHOULD BE WORN WHEN HANDLING THIS PRODUCT IF THERE IS POTENTIAL FOR MATERIAL TO CONTACT THE EYE.

§PAGE
KINEVAC (5 UG/VIAL)

PAGE 3 OF 4

HEALTH EFFECTS & FIRST AID (CONTINUED)

OTHER: KINEVAC IS INTENDED FOR INTRAVENOUS INJECTION, UNDER THE CARE OF A PHYSICIAN. IT CONTAINS SINCALIDE, A DRUG THAT IS USED TO STIMULATE OR EVACUATE THE GALLBLADDER. SINCALIDE FREQUENTLY CAUSES NAUSEA, ABDOMINAL PAIN OR DISCOMFORT, AND AN URGE TO DEFECCATE. DIZZINESS AND FLUSHING MAY ALSO OCCUR. ADVERSE EFFECTS USUALLY OCCUR IMMEDIATELY FOLLOWING INJECTION OF THE DRUG AND MAY LAST FOR A FEW MINUTES.

MEDICAL CONDITIONS AGGRAVATED

INJECTION OF THERAPEUTIC DOSES OF KINEVAC MAY CAUSE SMALL GALLBLADDER STONES TO BE EVACUATED, LEADING TO BLOCKAGE OF THE BILE DUCT; SENSITIVITY TO SINCALIDE. SINCALIDE SHOULD NOT BE ADMINISTERED TO PREGNANT WOMEN NEAR TERM. BECAUSE OF ITS EFFECT ON SMOOTH MUSCLE IT MAY BE POSSIBLE TO INDUCE LABOR PREMATURELY.

CARCINOGEN LISTS: IARC: NO NTP: NO OSHA: NO

TOXICITY: NO TOXICITY DATA ARE AVAILABLE.
ADDITIONAL INFORMATION ABOUT THERAPEUTIC USE AND EFFECTS OF THIS PRODUCT MAY BE FOUND IN THE PACKAGE INSERT SUPPLIED WITH THIS PRODUCT.

TARGET ORGANS: AT THERAPEUTIC DOSES THE COMPOUND EXERTS REVERSIBLE PHARMACOLOGIC EFFECTS ON THE GALLBLADDER.

FIRST AID FOR OVEREXPOSURE

EYE CONTACT: FLUSH WITH LARGE AMOUNTS OF WATER FOR 15-20 MINUTES.

SKIN CONTACT: WASH WITH SOAP AND WATER FOR 15-20 MINUTES.

INGESTION: GET MEDICAL ATTENTION IMMEDIATELY.

INHALATION: REMOVE TO FRESH AIR; IF DIFFICULTY IN BREATHING ADMINISTER OXYGEN. IF A PERSON IS NOT BREATHING ARTIFICIAL RESPIRATION CAN BE ATTEMPTED. GET MEDICAL ATTENTION IMMEDIATELY.

SPECIAL PROTECTION INFORMATION

IF MATERIAL HAS SPILLED, WORKERS SHOULD AVOID SKIN OR EYE CONTACT WITH, AND INHALATION OF THE POWDER. CHEMICAL SAFETY GOGGLES AND LATEX GLOVES SHOULD BE WORN WHEN HANDLING THIS FORMULATION. SPILLED POWDER MAY BE WETTED TO MINIMIZE DUST GENERATION. IN THE EVENT OF A LARGE SPILL, A NIOSH-APPROVED DUST/MIST RESPIRATOR SHOULD BE USED.

WORKERS SHOULD WASH THEIR HANDS AND FACE AFTER HANDLING THIS COMPOUND.

PROMPTLY REMOVE CONTAMINATED CLOTHING SHOULD CONTACT OCCUR. WASH CONTAMINATED CLOTHING BEFORE REUSE.

PERSONNEL WHO HANDLE THIS FORMULATION IN A NON-MANUFACTURING SETTING (E.G. AT A CLINICAL FACILITY) SHOULD USE EYE PROTECTION IF THERE IS POTENTIAL FOR THE MATERIAL TO CONTACT THE EYES. PERSONNEL WHO HANDLE THIS FORMULATION IN A MANUFACTURING SETTING SHOULD WEAR A GOWN, GLOVES AND CHEMICAL SAFETY GOGGLES.

SPECIAL PRECAUTIONS & COMMENTS

KINEVAC SHOULD BE STORED AT ROOM TEMPERATURE, 15-30 DEGREES C.

\$PAGE
KINEVAC (5 UG/VIAL)

PAGE 4 OF 4

SPECIAL PROTECTION INFORMATION (CONTINUED)

PERSONS WHO ARE ALLERGIC TO THIS SUBSTANCE SHOULD AVOID CONTACT WITH THIS SUBSTANCE.

DIAGNOSTIC AGENTS ARE INTENDED FOR USE UNDER DIRECTION OF A PHYSICIAN AND/OR UNDER THE CONDITIONS OF USE DESCRIBED ON THE LABEL. AS A GENERAL PRECAUTION, PERSONNEL WHO HANDLE THESE SUBSTANCES SHOULD AVOID CONTACT (INGESTION, INHALATION, SKIN AND EYE CONTACT) WITH THESE SUBSTANCES.

THIS MATERIAL SAFETY DATA SHEET IS INTENDED FOR USE BY PERSONNEL WHO HANDLE THIS MATERIAL AS PART OF THEIR JOB RESPONSIBILITIES. IT DOES NOT ADDRESS THE DIAGNOSTIC USE OF THIS MATERIAL. INFORMATION CONCERNING THE DIAGNOSTIC USE OF THIS SUBSTANCE SHOULD BE OBTAINED FROM FORMULATED PRODUCT PACKAGE INSERTS AND OTHER APPROPRIATE REFERENCES.

DOT SHIPPING CLASSIFICATION: NONE.

\$ENDDTR: